Nang Kuang Pharmaceutical Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
November 03, 2022
Share
Nang Kuang Pharmaceutical Co., Ltd. reported earnings results for the third quarter and nine months ended September 30, 2022. For the third quarter, the company reported sales was TWD 490.83 million compared to TWD 464.9 million a year ago. Net income was TWD 74.6 million compared to TWD 45.43 million a year ago. Basic earnings per share from continuing operations was TWD 0.74 compared to TWD 0.45 a year ago. Diluted earnings per share from continuing operations was TWD 0.74 compared to TWD 0.45 a year ago.
For the nine months, sales was TWD 1,339.44 million compared to TWD 1,330.7 million a year ago. Net income was TWD 190.23 million compared to TWD 144.48 million a year ago. Basic earnings per share from continuing operations was TWD 1.88 compared to TWD 1.43 a year ago. Diluted earnings per share from continuing operations was TWD 1.88 compared to TWD 1.43 a year ago.
NANG KUANG PHARMACEUTICAL CO., LTD. is principally engaged in the manufacture, processing and trading of western medicine. The company main products include injections, sterile injections, powder injections, hard capsules, bare ingots, film ingots, casing ingots, granules and creams, among others. The Company is also engaged in the manufacture, processing and trading of medical equipment. The Company distributes its products within the domestic market and to overseas markets.